Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 21st European Workshop for Rheumatology Research

Meeting abstract

The integration of functional genomics, combinatorial chemistry and nanotechnology into a miniaturized drug discovery process

M Auer

  • Correspondence: M Auer

Author Affiliations

Novartis Forschungsinstitut GmbH, Dermatology, Fluorescence based HTS-Technology Program, Vienna, Austria

Arthritis Res 2001, 3(Suppl A):L005-A42  doi:10.1186/ar153

The electronic version of this article is the complete one and can be found online at:


Received:15 January 2001
Published:26 January 2001

© 2001 2001 BioMed Central Ltd

Meeting abstract

Future concepts in miniaturized HTScreening technologies will concentrate on making optimal use of the two emerging technologies, combinatorial chemistry and functional genomics. To effectively exploit compounds from highly-parallel combinatorial synthesis and the high number of new target proteins from functional genomics, Novartis and Evotec BioSystems developed the CONA-BSP (confocal nanoscanning - bead scanning picking technology) as a novel high throughput - low hit-rate HTS process. In combination with the Novartis proprietary AIDA-Technology, quantitative on-bead confocal fluorescence screening can be combined with off-bead confirmation via a series of fluorescence techniques such as fluorescence anisotropy, or rotational correlation time applied to equilibrium binding studies.

Single molecule fluorescence spectroscopy and confocal nanoscanning/AIDA technology provide an optimal combination for a miniaturized automated uHTS process with high mechanistic resolution in functional and coupled assay systems.

References

  1. Fluorescence correlation spectroscopy: Lead discovery by miniaturized HTS.

  2. Auer M, Moore KeithJ, Meyer-Almes F-J, Guenther R, Pope AJ, Stoeckli KA:

    Drug Discovery Today,. 1998, 3:457-465. Publisher Full Text OpenURL

  3. Auer M, Gstach H:

    Fluorescent dyes (AIDA) for solid phase and solution phase screening. United States Patent, WO 00/37448. OpenURL

  4. Meyer-Almes FJ, Auer M: Enzyme inhibition assays with fluorescence correlation spectroscopy: A new algorithm for the derivation of kcat/Km and Ki values at substrate concentrations lower than the Michaelis Menten constant.

    Biochemistry 2000, 39(43):13261-13268. Publisher Full Text OpenURL

  5. The integration of single molecule detection technologies into miniaturized drug screening: Current status and future perspectives.

  6. Bühler C, Stöckli K, Auer M: .

    Review in press: Fluorescence Spectroscopy: Valeur/Brochon, Trends in Fluorescence Spectroscopy (Springer Verlag, 2001) OpenURL